IDO1 and cancer: Indirect evidence of interindividual variability in IDO activity, and/or inductibility, is also supported by several studies that showed that the development of IFN-α-induced neuropsychiatric symptoms only occurs in 20–50% of cancer- or hepatitis C-treated patients [15], [25], [26].